Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients-Reference-Cited by-同舟云学术

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients

Published:2020-10-15 Issue:2 Volume:1 Page:507-516
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Yamasaki Satoshi¹^ORCID,Kada Akiko²,Choi Ilseung³,Iida Hiroatsu⁴,Sekiguchi Naohiro⁵,Harada Naoko⁶,Sawamura Morio⁷,Shimomura Takeshi⁸,Komeno Takuya⁹,Yano Takahiro¹⁰,Yoshida Isao¹¹,Yoshida Shinichiro¹²,Sunami Kazutaka¹³,Hishita Terutoshi¹⁴,Takatsuki Hiroshi¹⁵,Ohshima Koichi¹⁶,Takeshita Morishige¹⁷,Saito Akiko M.²,Iwasaki Hiromi¹,Nagai Hirokazu⁴

Affiliation:

1. Department of Hematology and Clinical Research Institute National Hospital Organization Kyushu Medical Center Fukuoka Japan

2. Clinical Research Center National Hospital Organization Nagoya Medical Center Nagoya Japan

3. Department of Hematology National Hospital Organization Kyushu Cancer Center Fukuoka Japan

4. Department of Hematology National Hospital Organization Nagoya Medical Center Nagoya Japan

5. Department of Hematology National Hospital Organization Disaster Medical Center Tachikawa Japan

6. Department of Hematology National Hospital Organization Kumamoto Medical Center Kumamoto Japan

7. Department of Hematology National Hospital Organization Shibukawa Medical Center Shibukawa Japan

8. Department of Hematology National Hospital Organization Hiroshimanishi Medical Center Otake Japan

9. Department of Hematology National Hospital Organization Mito Medical Center Ibaraki Japan

10. Department of Hematology National Hospital Organization Tokyo Medical Center Tokyo Japan

11. Department of Hematologic Oncology National Hospital Organization Shikoku Cancer Center Matsuyama Japan

12. Department of Hematology National Hospital Organization Nagasaki Medical Center Omura Japan

13. Department of Hematology National Hospital Organization Okayama Medical Center Okayama Japan

14. Department of Hematology National Hospital Organization Himeji Medical Center Himeji Japan

15. Department of Hematology National Hospital Organization Kokura Medical Center Kitakyushu Japan

16. Department of Pathology School of Medicine Kurume University Kurume Japan

17. Department of Pathology Faculty of Medicine Fukuoka University Fukuoka Japan

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.111

Reference22 articles.

1. Differences in incidence and trends of haematological malignancies in J apan and the U nited S tates

2. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

3. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

4. Diffuse Large B-cell Lymphoma in the Elderly: A Review of Potential Difficulties

5. Schedule dependence of sensitivity to 2',2'‐difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours;Haperen VWR;Biochem Pharmacol,1994

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study;Cancer Medicine;2024-08

2. A note on confidence intervals for the restricted mean survival time based on transformations in small sample size;Pharmaceutical Statistics;2021-09-21